Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics sells another slug of its holding in Arrowhead

In total, Silence Therapeutics has now sold 6,358,850 Arrowhead shares on the open market, realising proceeds of US$23.0mln (£17.2mln)
Silence Therapeutics sells another slug of its holding in Arrowhead
The company will use the proceeds from the sale to fund working capital requirements

Silence Therapeutics plc (LON:SLN) said it has sold 2,317,693 shares in Arrowhead Pharmaceuticals Inc.(NASDAQ:ARWR) for an average price of US$3.60, reducing its holding in Arrowhead to 0.63%.

In total, Silence Therapeutics has now sold 6,358,850 Arrowhead shares on the open market, realising proceeds of US$23.0mln (£17.2mln). The average purchase price per share was US$1.65 and the average selling price of the 6,358,850 shares sold was US$3.62. The total profit recorded is therefore US$12.5mln, or £8.7mln.

READ: Silence Therapeutics offloads a slug of its Arrowhead holding at significant profit

The company will use the proceeds from the sale to fund working capital requirements.

Silence said it has determined that it may be advantageous to liquidate portions or all of its remaining holding of Arrowhead shares from time to time in an orderly manner consistent with prudent management of its investment.

READ: Silence Therapeutics' value climbs as it looks for IP redress

The Company still holds 472,509 common shares which represents 0.63% of Arrowhead.

 

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

PreveCeutical Medical bidding to be big player in preventive healthcare
October 10 2017
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
blood cells
October 23 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use